The interplay between EZH2 and other cell cycle targets (e.g., AURKA, CHEK1, CDKN1A) has also been reported in other contexts such as breast cancer, melanoma, non-Hodgkin’s lymphoma, T-cell acute lymphoblastic leukemia (49, 50). This evidence concerns the gene CDKN1A and breast cancer.